Evidence map›Paper›PMID 39553398›Full record

ArticleAdvances in radiation oncology2024

Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?

Penny Fang, Sonal S Noticewala, Susan Y Wu, Jillian R Gunther, Ethan B Ludmir, L Jeffrey Medeiros, Paolo Strati, Ranjit Nair, Chijioke Nze, Loretta J Nastoupil and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Penny FangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sonal S NoticewalaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Susan Y WuDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jillian R GuntherDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ethan B LudmirDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Paolo StratiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ranjit NairDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chijioke NzeDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Loretta J NastoupilDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sairah AhmedDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Luis Malpica CastilloDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Luis FayadDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jason WestinDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sattva NeelapuDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Christopher FlowersDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Auris HuenDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Swaminathan P IyerDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bouthaina DabajaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chelsea C PinnixDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Extranodal NK/T-cell lymphoma (ENKTCL) is rare in the Western Hemisphere and is commonly treated with combined modality therapy (CMT). Methods and Materials: We retrospectively reviewed 35 patients treated with Ann Arbor stage I/II ENKTCL between 1994 and 2015 at a large academic cancer center in the United States. Results: With 11.6 years median follow-up, median overall survival and progression-free survival were 13.5 and 7.5 years, respectively. Eighteen (51%) patients experienced disease relapse, with 5 regional nodal relapses, of which 2 experienced combined regional and distant relapses. All 5 regional nodal relapses occurred exclusively among patients not treated with elective nodal irradiation (ENI). ENI was associated with improved progression-free survival (hazard ratio [HR], 0.21; 95% CI, 0.09-0.52; Conclusions: In this Western Hemisphere cohort of early-stage ENKTCL patients treated with CMT, ENI may have a potential clinical benefit, particularly in patients who are treated with non-asparaginase-containing CMT, such as in patients treated with radiation alone, patients treated with less intensive chemotherapy concurrently, or patients who are unable to tolerate intensive chemotherapy.

Identifiers

PMID39553398
PMCPMC11565384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.